Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Feb 1;12(1):19.
doi: 10.21037/atm-23-1804. Epub 2023 Oct 30.

Liquid biopsy to tailor the treatment of advanced hormone receptor-positive breast cancer in the era of novel endocrine agents and CDK4/6-inhibitors

Elia Seguí  1   2   3 , Francesco Schettini  2   3   4
Affiliations
Editorial

Liquid biopsy to tailor the treatment of advanced hormone receptor-positive breast cancer in the era of novel endocrine agents and CDK4/6-inhibitors

Elia Seguí et al. Ann Transl Med. .
No abstract available

Keywords: CDK4/6-inhibitors; ESR1; bazedoxifene; endocrine resistance; liquid biopsy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-23-1804/coif). E.S. reports having obtained travel/accommodation paid by Gilead, Daiichi Sankyo, Novartis and Lilly, and personal fees for educational events from Novartis and Pfizer. F.S. reports having obtained travel/accommodation paid by Novartis and Gilead, and personal fees for educational events from Novartis, Daiichy-Sankyo and Gilead. The authors have no other conflicts of interest to declare.

Comment on

References

    1. Harbeck N, Bartlett M, Spurden D, et al. CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies. Future Oncol 2021;17:2107-22. 10.2217/fon-2020-1264 - DOI - PubMed
    1. Gao JJ, Cheng J, Bloomquist E, et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol 2020;21:250-60. 10.1016/S1470-2045(19)30804-6 - DOI - PubMed
    1. Schettini F, Giudici F, Giuliano M, et al. Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. J Natl Cancer Inst 2020;112:1089-97. 10.1093/jnci/djaa071 - DOI - PMC - PubMed
    1. Giuliano M, Schettini F, Rognoni C, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol 2019;20:1360-9. 10.1016/S1470-2045(19)30420-6 - DOI - PubMed
    1. Schettini F, Seguí E, Conte B, et al. Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report. Front Oncol 2022;12:1009352. 10.3389/fonc.2022.1009352 - DOI - PMC - PubMed